General Pre-Trial Screening Protocol for Infectious Diseases Research

The purpose of this general screening protocol is to facilitate recruitment into studies conducted at the Center for Virology and Vaccine Research (CVVR) and Division of Infectious Diseases at Beth Israel Deaconess Medical Center. This protocol will help us to determine whether a volunteer is eligible for completing the screening process and which protocols might best be suited to the participant.

Volunteers will be adults interested in participating in a clinical trial, such as a vaccine or therapeutic study, and particularly for studies conducted as part of the HIV Vaccine Trials Network. Occasionally, the screening protocol may be used for an observational study. This general screening protocol will help to determine the eligibility of potential volunteers for any clinical trials open for recruitment or soon to be opened. No investigational products will be administered under this protocol. All main vaccine or intervention studies will be submitted as separate applications to the appropriate regulatory agency as required by the sponsor.

Prescreening of volunteers may be done via telephone using an already approved script and RedCap questionnaire. Following the prescreening, the volunteer will be scheduled for an in-person clinic visit with a study clinician (MD, NP or RN). All participants in this study will be screened for safety, including a physical exam, vital signs and laboratory testing. This is to ensure that participants meet the appropriate inclusion and exclusion criteria related to safety in a clinical trial. The following study procedures will be performed at the Clinical Research Center at BIDMC:

• Informed Consent process completed before any other study activities are conducted
• Demographics
• Medical history
• Review of current medications
• Targeted physical exam including vital signs
• Behavioral risk assessment to determine risk of acquiring HIV
• Contraception status
• Blood or urine collection: on average, most safety screening laboratory tests will require no more than 60mL of blood which will be resulted in BIDMC's clinical laboratory. A urine sample may be collected for people of childbearing potential to determine pregnancy status.

Laboratory tests will be checked against eligibility criteria of open or soon-to-be opened clinical trials. If a test or exam result suggest that further medical evaluation or treatment may be necessary, the participant will be notified and referred to their care provider for further treatment. A copy of test results will be provided if requested.

Inclusion criteria

• 18 years of age or older at time of consent
• Available to participate for the planned duration of the clinical trials for which screening is being done
• Capable of giving signed informed consent

Exclusion criteria

• A condition, based on clinical judgement, which requires active medical intervention or monitoring to avert serious danger to the participant's health or well-being